This presentation will:

1) Review the rapid advances over the past decade in how lung cancer is diagnosed and treated.

2) Examine the role of molecular/biomarker testing in advanced stage non-small cell lung cancer for optimal therapy selection.

3) Discuss the evolving trends for molecular/biomarker testing in early-stage disease. 

Bio

Dr. Paul VanderLaan is an Associate Professor of Pathology at Harvard Medical School, and serves as the Director of Surgical Pathology, Director of Cytopathology, and the Director of Thoracic Pathology at Beth Israel Deaconess Medical Center. His clinical and research interests lie at the intersection of cytopathology and pulmonary pathology in the setting of both neoplastic and non-neoplastic lung disease, as well as thyroid cytology FNA reporting. He is the Editor-in-Chief of the Journal of the American Society for Cytopathology (JASC), and the co-editor of the recently published 3^rd edition of the Bethesda System for Reporting Thyroid Cytopathology.